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Abstract
Intestinal metaplasia in Barrett’s oesopha-
gus (BO) represents an important risk factor
for oesophageal adenocarcinoma. Instead, few
and controversial data are reported about the
progression risk of columnar-lined oesophagus
without intestinal metaplasia (CLO), posing
an issue about its clinical management. The
aim was to evaluate if some immunophenotyp-
ic changes were present in CLO independently
of the presence of the goblet cells. We studied
a series of oesophageal biopsies from patients
with endoscopic finding of columnar metapla-
sia, by performing some immunohistochemical
stainings (CK7, p53, AuroraA) combined with
histochemistry (Alcian-blue and Alcian/PAS),
with the aim of simultaneously assess the his-
tochemical features in cells that shows an aber-
rant expression of such antigens. We evidenced
a cytoplasmic expression of CK7 and a nuclear
expression of Aurora A and p53, both in goblet
cells of BO and in non-goblet cells of CLO, some
of which showing mild dysplasia. These find-
ings suggest that some immunophenotypic
changes are present in CLO and they can pre-
cede the appearance of the goblet cells or can
be present independently of them, confirming
the conception of BO as the condition charac-
terized by any extention of columnar epitheli-
um. This is the first study in which a combined
immunohistochemical/histochemical method
has been applied to Barrett pathology.
Introduction
Barrett’s oesophagus (BO) was endoscopi-
cally defined by the presence of at least 2 to 3
cm of columnar epithelium in the lower
oesophagus. Recently, the Global Evidence-
Based Consensus of Montreal defined Barrett
oesophagus as columnar metaplasia lining the
distal oesophagus, with specialized intestinal
metaplasia (IM) with goblet cells, or gastric
metaplasia with cardial type or fundic-oxyntic
type mucosa.1 The main feature of intestinal
metaplasia is the presence of Alcian blue-posi-
tive mucin-producing goblet cells. Moreover, in
clinical practice, the finding of cardial and/or
fundic mucosa without intestinal metaplasia2-4
in the distal oesophagus is frequent and it has
been reported as columnar-lined oesophagus
(CLO). However, it probably represents an
early reflux-lesion preceding an evident
Barrett phenotype with goblet cells, in keeping
with previous studies showing that CK7 is a
marker related to early phase of gastroe-
sophageal reflux, and it is present also in CLO
biopsies lacking of IM.5 BO with IM represents
an important risk factor for oesophageal ade-
nocarcinoma, in keeping with the progression
sequence metaplasia-dysplasia-adenocarcino-
ma. Chandrasoma et al. hypothesized that
patients with cardial metaplasia could poten-
tially progress towards dysplasia and adenocar-
cinoma through IM.6-7 Instead, few and contro-
versial data are reported in the literature about
the progression risk of CLO lacking of IM, giv-
ing rise to a question about the clinical man-
agement of this lesion. On this basis, we stud-
ied a series of oesophageal biopsies from
patients with endoscopic abnormalities related
to columnar metaplasia, by performing some
double and triple immunohistochemical/histo-
chemical stains (CK7/Alcian/PAS, p53/Alcian/
PAS, Aurora A/Alcian/PAS) in order to simulta-
neously assess the mucinous histochemical
features of the cells with aberrant expression
of such antigens. The aim of the study was to
evaluate if some immunophenotypic changes
were present in CLO cases without IM and if
these changes could precede the appearance of
the goblet cells or may be present independent-
ly of them. Aurora A maps in 20q13.2, a chro-
mosomal region frequently amplified and over-
expressed in several human malignancies
(breast, bladder, prostate, ovary, colon and pan-
creas).8 Recently its expression was evidenced
in Barrett adenocarcinoma and in CLO.9,10 In
experimental studies, the over-expression of
Aurora A was oncogenic and constantly associ-
ated with mutation of the gene Tp5311,12 that,
becoming unable to block the kinase activity of
the Aurora A, leads to a strong accumulation of
extra-copies of centrosomes.13 Cells without a
functional p53 and with high levels of Aurora A
are characterized by repeated cell cycles, until
they become aneuploid. These observations
identify the protein Aurora A as a prognostic
marker, being itself an accomplice of carcino-
genesis. To our knowledge, this is the first
study in which a combined immunohistochem-
ical/ histochemical method has been applied in
the study of Barrett pathology.
Materials and Methods
This is a retrospective study performed on
57 biopsies obtained from H. pylori-free
patients showing columnar metaplasia of the
lower oesophagus at the endoscopy. The con-
sent for study participation was obtained from
all patients. The study was approved by the
Institutional Ethic Committee. The cases were
retrieved from broader clinical records, con-
sisting of 819 oesophageal biopsies collected
between June 2006 and June 2012 and com-
prising 228 cases (27.8%) of columnar meta-
plasia (135 with BO and 93 with CLO) and 26
cases of adenocarcinoma (3.1%). 
Formalin-fixed, paraffin-embedded speci-
mens were retrieved from the Archives of the
Department of Pathology, University of
Palermo (Italy). For each patient, 4-quadrant
biopsy specimens have been taken every 2 cm
and stained with Hematoxylin-Eosin and
Alcian-PAS. The patients were divided into
three groups: i) Group A, 20 BO cases consist-
ing of IM, with Alcian blue-positive goblet cells;
ii) Group B, 17 cases of CLO consisting of
PAS+ columnar metaplasia without Alcian
blue positive goblet cells; iii) Group C, 20 cases
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with intermediate features of transitional
metaplasia (TM), consisting of PAS+ columnar
mucosa with only few cells showing initial pro-
duction of acid-Alcian blue positive-mucins,
but devoid of goblet cell morphology. All the
cases were stained with combined
double/triple immunohistochemical/histo-
chemical methods. The combined staining
method consists of two steps: in the first step
an immunohistochemical staining was per-
formed, according to the manufacturer’s
instructions (Universal LSAAB kit, Dako).
Primary antibodies used in this study were:
CK7 (Clone SP52; 1:100; Ventana), p53 (Clone
DO7; 1:200; Ventana) and Aurora A (Clone
EP1008Y; 1:100; Epitomics). Immunohisto -
chemical positivity was considered significant
when it was cytoplasmic for CK7, nuclear for
p53 and nuclear or nuclear/cytoplasmic for
Aurora A. As positive control for Aurora A and
p53, we referred to a case of adenocarcinoma
arising in the lower oesophagus (Barrett ade-
nocarcinoma). For Aurora A and p53, the posi-
tivity in at least 3% of the nuclei was consid-
ered significant. For CK7, cytoplasmic staining
in at least one gland was considered signifi-
cant. Negative controls, lacking primary anti-
body incubations, were included for each
immunohistochemical run. 
In the second step, a histochemical staining
was performed on the same sections previous-
ly subjected to the immunohistochemical
assay. At first, Alcian blue staining was per-
formed and the results of this double immuno-
histochemical/histochemical staining were
observed. Subsequently, PAS staining was
added (triple staining) and the results were
observed again. The histochemical stainings
were performed with only minor modifications
according to Poletti et al.14 For Alcian blue
staining, the sections were stained with Alcian
blue solution (pH 2.5) for 30 min at room tem-
perature, washed in running tap water for 10
min, rinsed in DI water, counterstained in
Mayer’s hematoxylin for 5 min and washed in
DI water. The acetic acid as mordant was not
used because it has no effect on the final
results. For PAS staining, sections were oxi-
dized in 0,5% periodic acid solution for 5 min,
rinced in DI water, placed in Schiff reagent for
15 min, washed in tap water for 5 min, coun-
terstained in Mayer’s hematoxylin for 1 min
and washed in DI water. Finally, the slides
were dehydrated, cleared and mounted.
Differentiation with hydrochloric acid was
omitted because it markedly reduces tissue
antigenicity and causes fading of the chro-
mogenic reaction when the immunohisto-
chemical staining is performed before PAS
staining.
Results
A case of adenocarcinoma of the lower
oesophagus (Barrett adenocarcinoma) is
showed in Figure 1a.  The tumor exhibited
strong nuclear positivity for p53 and Aurora A
(Figure 1b) and it was used as positive control
for the immunohistochemical stains with
these antibodies. CK7 was positive in all the
three groups; it was more diffusely and strong-
ly expressed in group A, while focally and more
weakly in groups B and C.
Group A. Both Aurora A and  p53 immunos-
tainings were positive in the nuclei of Alcian
blue+ goblet cells in 6 of 20 cases (Figure 2a).
Noteworthy, they were positive also in nuclei
of PAS+/Alcian blue negative columnar cells,
whereas adjacent Alcian blue+ goblet cells
were negative [Figure 2b]. 
Group B. Eight of 17 cases showed focal
nuclear positivity for Aurora A and p53 in
PAS+/Alcian blue negative columnar cells
(Figure 3 b,c). Noteworthy, CK7 was expressed
just in the same Aurora A/p53 positive areas
(Figure 3d).
Group C. Four of 20 cases showed positive
immunostaining both for Aurora A and p53.
Aurora A was positive both in Alcian blue-neg-
ative cells (Figure 4a) and in cells with initial
production of Alcian blue-positive mucins, but
lacking of goblet cell morphology (cells with
intermediate features between IM and CLO)
(Figure 4b). As in the previous group, p53 and
CK7 were  expressed in the same areas,
despite the absence of IM.
Noteworthy, the sequential histochemical
steps of the double and triple staining did not
affect the immunohistochemical results
obtained in the previous step. The results are
summarized in Table 1.
Brief Report
Table 1. Results of the sequential histo-
chemical steps of the double and triple
staining.
Cases Ck7 Aurora A/p53
Group A 20 20 6
Group B 17 17 8
Figure 1. Adenocarcinoma of the oesophagus. a) Hematoxylin and eosin stain. b) Aurora
A immunohistochemical stain. Strong nuclear positivity in neoplastic cells.
Figure 2. Group A. Intestinal metaplasia with goblet cells. a) Positivity for Aurora A in
nuclei of glands comprising Alcian blue+ goblet cells (arrows). b) In another field of the
same case, Aurora A was positive only in nuclei of Alcian blue-/PAS+ columnar cells
(arrows), whereas the gland with Alcian blue+ goblet cells was negative (asterisk). a,b)
Triple Aurora A/Alcian blue/PAS stain. 
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Discussion 
The combined use of immunohistochemi-
cal/histochemical staining methods has rarely
been reported in the literature. Wong et al.
used the double Alcian blue/Chromogranin A
and Alcian-blue/Mib-1 staining in specimen of
gastric mucosa with intestinal metaplasia and
neuroendocrine hyperplasia, to distinguish the
proliferating cellular component.15 To our
knowledge, a double histochemical/immuno-
histochemical method has not been applied to
the study of oesophageal pathology.
In our study, all the cases stained positively,
at least focally, for CK7, considered an early
marker of gastroesophageal reflux because it
is usually absent in normal fundic and cardial
mucosa, but present in columnar metaplastic
mucosa of the oesophagus, including cases
lacking of IM.5 Furthermore, our study showed
nuclear expression of Aurora A kinase in
columnar metaplasia lacking of goblet cells
(group B), often correlating with p53 nuclear
expression. The Aurora A kinase belongs to
serine/threonine group of kinases that operate
as key regulators of mitosis and it has a role in
the cell cycle progression. Several studies
showed that a deregulation in the expression
and activity of this protein leads to defects in
the assembly of the centrosome and of the
mitotic spindle, aneuploidy, genetic instability
and tumourigenesis.11,12,16-22 Nuclear positivity
has been reported in hormone-related (breast,
ovary and prostate) human cancers associated
with a poor outcome,23,24 but not in non-hor-
mone responsive conditions, such as in the
oesophageal columnar metaplasia and in the
Barrett adenocarcinoma. Previously, we evi-
denced the overexpression of Aurora A with
RT-PCR in cases of columnar mucosa with and
without IM.10
In the present study, we evidenced Aurora A
immunohistochemical overexpression in the
nuclei of PAS+ cells. In the group A we found
nuclear Aurora A-positive staining in some
Alcian blue+ goblet cells of Barrett mucosa,
but, noteworthy, other goblet cells did not stain
for Aurora A, whereas the adjacent PAS+
columnar cells stained positively. This is in
keeping with the findings of Group B cases,
lacking of IM, in which Aurora A was present in
the nuclei of PAS+ columnar cells. 
The over-expression of Aurora A in non-gob-
let cells may support the recently introduced
conception of BO without intestinal metapla-
sia,1 in contrast with the definition in which
the goblet cells represented an essential pre-
requisite for the diagnosis of BO and an
obliged step in the cancer progression. In fact,
the definition of BO is still confusing and
ambiguous. According to the American College
of Gastroenterology25 and to the American
Gastroeneterological Association,26 intestinal
metaplasia is the only type of oesophageal
columnar epithelium that clearly predisposes to
malignancy and it is still required for the diag-
nosis of BO. Furthermore, our findings are in
keeping with Kelty et al., who observed that
patients with CLO lacking of IM on biopsy have
a similar cancer risk to those with specialized
IM, so they conclude that IM is not essential for
cancer risk.27 Of course, since the carcinogen-
esis is a multistep process consisting of many
overlapping mutations, the over-expression of
Aurora A in the columnar mucosa, with or
without IM, should not be considered a condi-
tion necessarily leading to the tumour, but a
potentially reversible condition after stopping
or decreasing of the stimulus. The appearance
of Aurora A and p53 nuclear positivity, togeth-
er with the reflux-related CK7 cytoplasmic pos-
itivity, in areas lacking of IM, could suggest
Brief Report
Figure 3. Group B. Columnar lined oesophagus. a) Hematoxylin and eosin stain. b)
Double Aurora A/Alcian blue stain showed Alcian blue negativity and Aurora A nuclear
positivity (arrows). c) Triple p53/Alcian blue/PAS stain showed cytoplasmic PAS positiv-
ity and p53 nuclear positivity (arrows). d) Triple Ck7/Alcian blue/PAS stain shows Ck7
positivity in Alcian blue-/PAS+ cells. 
Figure 4. Group C. Mucosa with a few cells with intermediate features between intestin-
al metaplasia and columnar-lined oesophagus, showing initial production of Alcian blue
positive mucins, but lacking of goblet cell morphology. a) Aurora A positivity both in
Alcian blue negative cells (arrows); double Aurora A/Alcian blue stain. b) Aurora A pos-
itivity in cells with initial production of acid mucins (arrows); triple Aurora A/Alcian
blue/PAS stain).
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another way besides the traditional IM-dyspla-
sia-adenocarcinoma sequence. In keeping with
our immunophenotypical findings, we hypoth-
esize a cancer sequence, in which CK7/
AuroraA/p53/PAS+ columnar mucosa could
represent an intermediate step of the carcino-
genesis, independently from the presence of
intestinal Alcian blue+ goblet cells (Figure 5).
Recently, in fact, adenocarcinoma of gastroe-
sophageal junction arising from cardial type
metaplasia have been described,28 suggesting
again the hypothesis of a double pathway pre-
viously reported by us.5
Noteworthy, in our study, consisting of 819
oesophageal biopsies collected between June
2006 and June 2012, we found 26 cases of ade-
nocarcinoma (3.1%), 25 of which aroused in
patients without a known clinical history of BO,
lacking previous endoscopy and never treated
with GERD therapy. On the contrary, none of
228 patients with endoscopic and histologic
columnar-lined oesophagus (135 with BO and
93 with CLO), treated with constant therapy for
GERD symptoms, developed a high-grade dys-
plasia/adenocarcinoma, during a mean follow-
up of 5 years (range 1-12) with bi-annual
endoscopy and biopsy. Only one case of CLO,
untreated, progressed to BO with dysplasia
(Figure 6). Given our results, we think that the
immunophenotypical alterations (such as
Aurora A and p53 expression) in some cells of
CLO cases could be by themselves responsible
of a risk progression, despite the absence of IM.
Therefore, in our view, also CLO patients
require an appropriate management, because
the outcome is not ab initio predictable. Of
course, in consideration of the low risk of can-
cer progression, both in CLO and BO patients
treated with PPI therapy, and of the necessity to
refine the surveillance program to obtain a good
cost/benefit ratio, we think that a more long-
term interval of endoscopies (e.g., a 3-year
interval) could be enough if BO and CLO cases
are properly treated. PPI therapy, in fact, could
be useful not only for the GERD symptoms but
also to reduce the risk of cancer progression. 
In conclusion, the combined staining
method allowed us to simultaneously evidence
the type of mucins produced by the columnar
cells and the immunophenotypical expression
of Aurora A, p53 and CK7 that may be indica-
tive of an early phase of the carcinogenetic
pathway independently from the IM step.
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